Virtu Financial’s Denali Therapeutics DNLI Stock Holding History

Virtu Financial’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$833K	Buy	+43,362	New	+$863K	0.03%	373
2025 Q3	–	Sell	-18,438	Closed	-$258K	–	1594
2025 Q2	$258K	Buy	+18,438	New	+$260K	0.01%	814
2024 Q1	–	Sell	-15,576	Closed	-$334K	–	1553
2023 Q4	$334K	Buy	+15,576	New	+$308K	0.03%	563
2021 Q1	–	Sell	-3,373	Closed	-$283K	–	1688
2020 Q4	$283K	Sell	3,373 -4,428	-57%	-$268K	0.03%	667
2020 Q3	$280K	Buy	+7,801	New	+$235K	0.05%	462
2019 Q4	–	Sell	-10,614	Closed	-$163K	–	1517
2019 Q3	$163K	Buy	+10,614	New	+$203K	0.01%	1010
2018 Q3	–	Sell	-12,274	Closed	-$187K	–	1661
2018 Q2	$187K	Buy	+12,274	New	+$231K	0.01%	1531

Other funds holding DNLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Virtu Financial's DNLI Position: Q1 2026 in Review

Virtu Financial opened a new position in Denali Therapeutics (DNLI) in Q1 2026: 43,362 shares worth $833K. The stake represents 0.03% of the portfolio and ranks #373 among its holdings. This is a return to the name: Virtu Financial previously reported a position in DNLI as recently as Q2 2025.

Virtu Financial first reported a position in DNLI in Q2 2018 and has held it in 7 quarters since. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

Virtu Financial held 43,362 shares of Denali Therapeutics worth $833K as of Q1 2026.
Denali Therapeutics was a new Virtu Financial position in Q1 2026.
Denali Therapeutics made up 0.03% of Virtu Financial's portfolio in Q1 2026, its #373 holding.
Virtu Financial first reported a position in Denali Therapeutics in Q2 2018 and has held it in 7 quarters since.
269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.